Profil
David Hyman has worked as a Chief Medical Officer at Eli Lilly & Co. since 2023 and at Loxo Oncology, Inc. since 2020.
Aktive Positionen von David Hyman
| Unternehmen | Position | Beginn |
|---|---|---|
| LOXO ONCOLOGY INC | Chief Tech/Sci/R&D Officer | 01.01.2020 |
| ELI LILLY AND COMPANY | Chief Tech/Sci/R&D Officer | 16.10.2023 |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| ELI LILLY AND COMPANY | Health Technology |
| Private Unternehmen | 1 |
|---|---|
Loxo Oncology, Inc.
 Loxo Oncology, Inc. Pharmaceuticals: MajorHealth Technology Loxo Oncology, Inc. is a biopharmaceutical company, which engages in the development of small molecule therapeutics for the treatment of cancer. It focuses on genetic alterations, targeted therapies, and genetic testing. The company was founded by Joshua H. Bilenker in May 2013 and is headquartered in Stamford, CT. | Health Technology |
